Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
1,112
Recruiting, any sponsor type, condition "breast cancer"
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting1,112
- Completed3,695
1,112 trials
Showing 1 to 25, recently updated first.
- Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low TrialPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT07391774 · 1,978 participants (planned) · Start Aug 10, 2026 · Primary completion Jul 31, 2029
Drug: Anastrozole; Chemotherapy and 3 more · For: Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8 and 2 more
Sites: Jonesboro, Arkansas; Auburn, California; Berkeley, California · 264 sites in all
Virginia Commonwealth UniversityAcademic, hospital or other
NCT06185205 · 170 participants (planned) · Start Dec 12, 2023 · Primary completion Jan 31, 2031
Drug: Accelerated partial breast irradiation · For: Breast Cancer
Sites: Richmond, Virginia
AstraZenecaAstraZeneca (AZN)
NCT06103864 · 625 participants (planned) · Start Nov 23, 2023 · Primary completion Jul 28, 2027
Drug: Dato-DXd; Durvalumab and 5 more · For: Breast Cancer
Sites: Daphne, Alabama; Springdale, Arkansas; Duarte, California · 318 sites in all
- Paclitaxel Oral Solution in Triple Neagtive Breast Cancer Neoadjuvant Therapy: A Dose-Finding StudyRecruiting
Liu ShuAcademic, hospital or other
NCT07739485 · 30 participants (planned) · Start Jul 30, 2026 · Primary completion Jul 30, 2027
Drug: Epirubicin and cyclophosphamide followed by paclitaxel oral solution · For: Triple -Negative Breast Cancer
Sites: Guiyang, China
National Cancer Institute (NCI)NIH
NCT04222413 · 116 participants (planned) · Start Oct 27, 2020 · Primary completion Dec 31, 2027
Drug: Metarrestin · For: Advanced Solid Tumors; Metastatic Pancreatic Cancer; Pediatric Solid Tumor and 3 more
Sites: Fairway, Kansas; Bethesda, Maryland
- Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast CancerPivotal-lookingRecruiting
SWOG Cancer Research NetworkResearch network
NCT05929768 · 2,400 participants (planned) · Start Sep 15, 2023 · Primary completion Mar 31, 2033
Drug: Carboplatin; Cyclophosphamide and 4 more · For: Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8 and 2 more
Sites: Birmingham, Alabama; Anchorage, Alaska; Fairbanks, Alaska · 963 sites in all
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT07591155 · 22 participants (planned) · Start May 13, 2026 · Primary completion Dec 2027
Drug: BL-ARC002 · For: Lung Cancer; Breast Cancer; Head and Neck Squamous Cell Carcinoma and 1 more
Sites: Tianjin, China
- A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.Pivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07062965 · 400 participants (planned) · Start Aug 5, 2025 · Primary completion Jul 22, 2027
Drug: PF-07248144; Fulvestrant and 2 more · For: Breast Cancer
Sites: Anchorage, Alaska; Chandler, Arizona; Gilbert, Arizona · 432 sites in all
- Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast CancerPivotal-lookingRecruiting
Olema Oncology, Inc.Industry
NCT07085767 · 1,000 participants (planned) · Start Nov 3, 2025 · Primary completion Dec 2028
Drug: Palazestrant; Letrozole-matching placebo and 3 more · For: Breast Cancer; Locally Advanced Breast Cancer; Metastatic Breast Cancer and 2 more
Sites: Hot Springs, Arkansas; Beverly Hills, California; La Jolla, California · 209 sites in all
- Phase 1 Study of OP-3136 in Advanced or Metastatic Solid TumorsPivotal-lookingRecruiting
Olema Oncology, Inc.Industry
NCT06784193 · 180 participants (planned) · Start Dec 16, 2024 · Primary completion May 30, 2027
Drug: OP-3136; Fulvestrant and 1 more · For: Advanced or Metastatic ER+ HER2- Breast Cancer (mBC); Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC); Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC) and 3 more
Sites: Gilbert, Arizona; Aurora, Colorado; Sarasota, Florida · 25 sites in all
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT07100106 · 285 participants (planned) · Start Oct 7, 2025 · Primary completion Aug 31, 2028
Drug: GDC-4198; Giredestrant and 1 more · For: Breast Cancer
Sites: Huntsville, Alabama; Tucson, Arizona; Duarte, California · 77 sites in all
Regor Pharmaceuticals Inc.Industry
NCT07524322 · 63 participants (planned) · Start Jul 21, 2026 · Primary completion Apr 2028
Drug: RGT-490 · For: Breast Cancer; Ovarian Cancer; Endometrial Cancer and 6 more
Sites: Los Angeles, California; Boston, Massachusetts; Pittsburgh, Pennsylvania · 7 sites in all
- Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast CancerPivotal-lookingRecruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityAcademic, hospital or other
NCT07061717 · 474 participants (planned) · Start Jul 16, 2025 · Primary completion Jul 1, 2029
Drug: Palbociclib 125mg qd (3 weeks of treatment followed by 1 week off) + Anastrozole 1mg qd / Letrozole 2.5mg qd / Exemestane 25mg qd; Palbociclib 125mg qd (3 weeks of treatment followed by 1 week off) + Anastrozole 1mg qd / Letrozole 2.5mg qd / Exemestane 25mg qd + Hydroxychloroquine 600mg bid and 1 more · For: Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
Sites: Guangzhou, China
Tethra Biosciences Inc.Industry
NCT05358379 · 330 participants (planned) · Start Apr 14, 2022 · Primary completion Nov 2028
Drug: THT140 · For: Solid Tumor, Adult Lymphoma
Sites: New York, New York; Houston, Texas; Seattle, Washington · 5 sites in all
University of WashingtonAcademic, hospital or other
NCT07721259 · 60 participants (planned) · Start Dec 15, 2026 · Primary completion Jul 16, 2029
Drug: CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine; Recombinant Granulocyte-Macrophage Colony-Stimulating Factor · For: Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8 and 1 more
Sites: Seattle, Washington
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06926868 · 600 participants (planned) · Start Sep 11, 2025 · Primary completion Mar 13, 2028
Drug: Iza-bren; Nab-paclitaxel and 4 more · For: Breast Neoplasms
Sites: Hot Springs, Arkansas; Cerritos, California; Long Beach, California · 296 sites in all
Stemline Therapeutics, Inc.Industry
NCT05386108 · 73 participants (planned) · Start Aug 31, 2022 · Primary completion Aug 2027
Drug: Elacestrant; Abemaciclib · For: Breast Neoplasms; Brain Neoplasms; Neoplasms by Site and 5 more
Sites: Fullerton, California; Los Angeles, California; Urbana, Illinois · 86 sites in all
National Cancer Institute (NCI)NIH
NCT06195306 · 66 participants (planned) · Start Jul 28, 2025 · Primary completion Jan 1, 2027
Drug: Omega-3-Acid Ethyl Esters; Tamoxifen · For: Breast Atypical Hyperplasia; Breast Carcinoma; Breast Ductal Carcinoma In Situ and 1 more
Sites: Kansas City, Kansas; Ann Arbor, Michigan; Columbus, Ohio
- A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid TumorsPivotal-lookingRecruiting
Arvinas Inc.Industry
NCT07749586 · 499 participants (planned) · Start Jul 29, 2026 · Primary completion Mar 31, 2031
Drug: ARV-6723; Pembrolizumab and 1 more · For: Advanced Solid Tumor
Sites: Boston, Massachusetts; New York, New York; Huntersville, North Carolina · 5 sites in all
UNC Lineberger Comprehensive Cancer CenterAcademic, hospital or other
NCT07276880 · 32 participants (planned) · Start Mar 17, 2026 · Primary completion Nov 2027
Drug: Neoadjuvant Pembrolizumab · For: Breast Cancer; Triple Negative Breast Cancer (TNBC); HER2-Negative Breast Carcinoma and 1 more
Sites: Chapel Hill, North Carolina
Tianjin Medical University Cancer Institute and HospitalAcademic, hospital or other
NCT07949695 · 30 participants (planned) · Start Nov 1, 2026 · Primary completion May 31, 2028
Drug: trastuzumab rezetecan (SHR-A1811) Toripalima、Endocrine therapy(ET) · For: HR Positive/HER2 Low Breast Cancer; Neoadjuvant Therapy; SHR-A1811 and 1 more
Sites: Tianjin, China
- A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid TumorsPivotal-lookingRecruiting
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT07488676 · 150 participants (planned) · Start May 4, 2026 · Primary completion Jul 31, 2029
Drug: ASP546C · For: Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma; Pancreatic Adenocarcinoma
Sites: Birmingham, Alabama; Los Angeles, California; Orange, California · 35 sites in all
Isabelle HenskensAcademic, hospital or other
NCT07146295 · 1,150 participants (planned) · Start Apr 18, 2025 · Primary completion Feb 2027
Drug: Technetium (99mTc); Indocyanine Green · For: Breast Cancer; Sentinel Lymph Node Biopsy (SLNB); Sentinel Lymph Node Detection and 6 more
Sites: Alkmaar, Netherlands; Hengelo, Netherlands; Hoofddorp, Netherlands · 7 sites in all
- Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast CancerPivotal-lookingRecruiting
Shanghai Yizhong Pharmaceutical Co., Ltd.Industry
NCT06143553 · 168 participants (planned) · Start Sep 25, 2023 · Primary completion Dec 31, 2027
Drug: Paclitaxel Polymeric Micelles for Injection; Eribulin Mesilate injection and 4 more · For: Metastatic Breast Cancer (MBC)
Sites: Nanjing, China; Shanghai, China · 3 sites in all
Alison StopeckAcademic, hospital or other
NCT06220214 · 30 participants (planned) · Start Mar 6, 2024 · Primary completion Jul 31, 2027
Drug: Omnipaque 350mgI/mL Solution for Injection · For: Breast Cancer; Locally Advanced Breast Cancer; Neoadjuvant Chemotherapy and 3 more
Sites: Stony Brook, New York
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.